Our Experience
Ged Wilkinson BEng, PG Cert, CEng, MIET
Ged holds a BEng in Electronics and Communications Engineering from the University of Leeds and a Postgraduate Certificate in Organisational Change from Ashridge Business School. He is a registered Chartered Engineer and a Member of the Institute of Engineering and Technology.
He has over 40 years’ experience of developing and delivering innovative technologies and advanced operational capabilities across the UK Government and National Security and Defence Community. As well as representing the UK with overseas Governments.
He has extensive experience in Space and Advanced Telecommunications, as well as across a broad range of other technology areas, from autonomous systems and robotics to advanced semiconductors and quantum technologies. He is particularly passionate about emerging technologies.
Christine Wilkinson Blanc MD MSc
Christine trained as a specialised physician in the Onco-Haematology, Immunology and Biology departments of the University Hospital of Lille in France; she also has a Master of Science in Immunology.
She has over 40 years’ experience in the pharmaceutical industry, mostly in oncology/and haematology, covering a wide range of products including targeted therapies, cytotoxic agents, growth factors, monoclonal antibodies and diagnostic and imaging products.
Her core experience is in:
– Clinical research with over 10 years working on R&D projects at Rhone-Poulenc Rorer/Aventis, Roche, Ariad Pharmaceuticals and Antisoma Ltd.
– Medical & Disease Strategy primarily in imaging and diagnostics at Amersham/GE Healthcare (over 4 years)
– Medical Affairs with 4 years of coordinating international oncology programs and developing a structured medical organisation in emerging markets at Rhone-Poulenc Rorer/Aventis and several years in national roles in France (Roche) and the UK (GSK).
Clinical Research
Christine has been involved in planning, conducting, and reporting over 30 Phase I (single agents and combinations of drugs), II, III, or IV trials in patients with solid and haematological tumours worldwide. She has extensive experience with regulatory documents including PIPs, IMPDs, licence renewals (Plavix), orphan drug dossiers (imatumumab in Europe), and, moreover, new drug applications (ISE, ISS, clinical overview ) with several successful submissions, e.g.Taxotere, Campto and Avastin (lung cancer).
Her experience includes all aspects of clinical research with efficient collaboration with internal and external partners such as clinical operations, biometrics and data management, drug safety, pharmacoeconomics, pharmacodynamics & pharmacokinetics, etc.
Medical and Disease Strategy
Christine’s experience included providing strategic medical and scientific direction to marketing (downstream) and research and development (upstream) teams, and contributing to the definition of development, registration, and commercialisation strategies for oncology/haematology drugs and products in the imaging and diagnostics arenas. She has assessed in-licensing opportunities (GE Healthcare) and contributed to offering memos (Ariad). This has included the medical/scientific evaluation of new molecular entities and techniques (over 100 at GE Healthcare) and recommendations on their medical perspectives.
International Medical Affairs
She has extensive experience in European and emerging markets, has worked efficiently with affiliate organisations, led local and regional medical development plans, and contributed to marketing strategies. She has a strong understanding of local and regional epidemiology and treatment paradigms for key cancers, and can effectively assess medical needs and prioritise clinical indications within an oncology portfolio. A major success was helping set up a structured medical organisation in emerging markets and building its knowledge of oncology and clinical development.